UPDATE: Genentech (RHHBY) Says Phase III Study of Lampalizumab for Geographic Atrophy Didn’t Meet Primary … – StreetInsider.com

UPDATE: Genentech (RHHBY) Says Phase III Study of Lampalizumab for Geographic Atrophy Didn’t Meet Primary … – StreetInsider.com

UPDATE: Genentech (RHHBY) Says Phase III Study of Lampalizumab for Geographic Atrophy Didn’t Meet Primary … – StreetInsider.com
Published on 2017-09-08